WATERTOWN, Mass. — Sonata Therapeutics, a biotechnology company developing a new class of therapeutics called Network Medicines™, and the Champalimaud Foundation, a world leader in biomedical research and academic medicine, today announced a research collaboration for the development of Sonata’s novel Network Medicine, SNT-3012. The partnership will drive the continued...
Latest News
SOUTH SAN FRANCISCO, Calif. — SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9th in Orlando, Florida. SonoThera’s...
SOUTH SAN FRANCISCO, Calif. — SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the American Society of Nephrology’s annual meeting being held November 5-9 in Houston, Texas. The poster presentation focuses...
BOSTON, Mass. and ROLLE, Switzerland – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma (RCC), with the results...
Beijing, China – Hepatocellular carcinoma (HCC) is a common disease in human history and one of the main causes of cancer-related death. Sorafenib (SORA) is the best representative of angiogenesis inhibitors and is currently being commonly used in the treatment of advanced HCC as a first-line drug. Although SORA improves...
Philadelphia, PA — Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are medications that lower blood sugar levels among other effects, provide kidney- and heart-related benefits to patients with and without diabetes. An exploratory analysis recently uncovered the effects of sotagliflozin, a dual SGLT1 and 2 inhibitor, in patients with type 2 diabetes and...
In patients with pulmonary arterial hypertension (PAH) receiving background therapy, treatment with sotatercept led to significant reductions in pulmonary vascular resistance (PVR), according to study results published in the New England Journal of Medicine. Researchers randomly assigned 106 patients with PAH (mean age, 48.3±14.3 years) who were receiving stable background therapy...
The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indications The study will be conducted in the US and selected European countries and will begin in the first half of 2022 BASEL, Switzerland – SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group,...
PRAGUE, BASEL, Switzerland & BOSTON, Mass. — SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced favorable preclinical results supporting the development of SOT106, its antibody-drug conjugate for the treatment of sarcoma, at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 12-15, 2025, in...
SEATTLE, Washington — Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 for the Treatment of Meniere’s Disease (MD). SPI-1005, a novel oral anti-inflammatory drug, received Breakthrough Therapy Designation (BTD) in late 2025. MD is a complex inner ear...